THR 687Alternative Names: THR-687
Latest Information Update: 30 Mar 2016
At a glance
- Originator Galapagos NV
- Developer ThromboGenics
- Mechanism of Action Integrin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic retinopathy